Lenograstim works by binding to specific receptors on the surface of hematopoietic progenitor cells in the bone marrow. This binding stimulates the proliferation, differentiation, and maturation of neutrophils, thereby enhancing the immune systemâs ability to fight infections. This is particularly crucial for cancer patients who are undergoing treatments that suppress bone marrow activity.
